Paul Tudor Jones Allakos Inc. Transaction History

Tudor Investment Corp Et Al

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	BUY	$4.3 - $8.27 $223,286 - $429,436	51,927 New	51,927 $231,000
Q3 2022 Nov 14, 2022	BUY	$3.02 - $6.12 $13,360 - $27,074	4,424 Added 15.81%	32,411 $198,000
Q2 2022 Aug 15, 2022	BUY	$2.6 - $6.14 $72,766 - $171,840	27,987 New	27,987 $88,000
Q1 2022 May 16, 2022	SELL	$5.08 - $9.81 $203,880 - $393,714	-40,134 Closed	0 $0
Q4 2021 Feb 14, 2022	BUY	$8.55 - $111.89 $343,145 - $4.49 Million	40,134 New	40,134 $393,000

64.7M

47.1K

Ticker ALLK
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 84,726,096
Market Cap $89.8M
Description
Allakos Inc., a clinical stage biopharmaceutical company, develops therapeutics that target immunomodulatory receptors present on immune effector cells in allergy, inflammatory, and proliferative diseases. The company's lead monoclonal antibody is lirentelimab (AK002), which is in a Phase III study for the treatment of eosinophilic gastritis and...

Get notified when there are updates to the investment portfolio of Tudor Investment Corp Et Al, based on Form 13F filings with the SEC.

Stay updated on Tudor Investment Corp Et Al and Paul Tudor Jones with notifications on news.